Biotech billionaire’s plan to beat cancer

Meet Patrick Soon-Shiong, the LA billionaire reinventing your health care 02-05-14, by Bradley J. Fikes, U-T San Diego It’s hard to think of a quest more audacious than taming cancer, which has resisted the efforts of medicine for thousands of years. Far older than humanity, cancer has been found in the 70 million-year-old bones of dinosaurs. But the life of biotech billionaire Dr. Patrick Soon-Shiong is full of audacious ventures. Born in apartheid-era South Africa, Soon-Shiong excelled as a surgeon despite discrimination because of his Chinese ancestry. In the United States, he pioneered a safer and more effective way of delivering the breast cancer drug paclitaxel, and amassed $9 billion through his entrepreneurship. Soon-Shiong discussed his plan to curb cancer with an audience in La Jolla Wednesday evening, the third in a series of talks held by UC San Diego Extension and the Center for Ethics in Science and Technology. The talks are intended to stimulate new ways of thinking to make progress against cancer. In a nutshell, Soon-Shiong proposes to use the power of what’s called “Big Data” to track the path of cancer. That path starts with mutations in the genome, continues through the messenger molecules of RNA and ends with the proteins made by RNA. With the exact pathway for each cancer known, Big Data pulls out potential drugs known to act against the suspect proteins, and sends the recommendations to the doctor’s computer, or perhaps smartphone. Moreover, the likely steps each cancer may take will be plotted, allowing doctors to get ahead of drug resistance. This vision is already happening, Soon-Shiong said. For example, he’s...

NANTOMICS Unveiled at J.P. Morgan 32nd Annual Healthcare Conference

NANTOMICS Unveiled at J.P. Morgan 32nd Annual Healthcare Conference With a vision towards the next generation comprehensive genomic and proteomic diagnostic tool for personalized medicine Dr. Patrick Soon-Shiong launches NANTOMICS Dr. Patrick Soon-Shiong will present at the JPMorgan Healthcare Conference on Wednesday, January 15, 2014 at 3:30 p.m. PST at the Westin St. Francis Hotel in San Francisco JPMorgan Healthcare Conference 2014 Dr. Patrick Soon-Shiong today announced the launch of NANTOMICS, the first fully integrated next generation Genomic and Proteomic Molecular Diagnostic Company dedicated to providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at point of care. NantOmics is the first and only molecular diagnostics company to pioneer an integrated approach identifying the genomic and proteomic variances that initiate and drive disease to provide actionable and personalized solutions for practitioners and patients. Insights of personalized molecular drivers of cancer are thus derived not just from DNA alterations alone, but integrated to true cellular pathway levels. NANTOMICS is the only molecular diagnostic company offering such comprehensive tumor profiling from the nucleotide to the peptide using the same tumor cells. The company operates through integrated segments to holistically profile the molecular basis of disease (from tissue to DNA to RNA to protein to drug): 1. Genomics: Cloud-based whole genome analysis with computation of genomic variances in near real-time between normal germline and tumor tissue from the same patient: Transporter™: The only platform software that integrates into sequencing Instruments at point of care to securely transfer unassembled data (Big Data) from the sequencing instrument to the cloud. High speed transfer client that encrypts (using military-grade algorithms)...

Billionaire Researcher On A Quest To Kill Cancer

The Orange County Register – by Meg Tirrell – Bloomberg News – Jan 31, 2013 On his quest to kill Cancer, L.A.’s wealthiest resident forms a new company aimed at changing the method by which the often deadly disease is attacked by medicine. Patrick Soon-Shiong, the physician who founded and sold two drug companies to become Los Angeles’ wealthiest resident, is starting a company with the goal of changing the way cancer is attacked. Called NantOmics, the company will build on the knowledge Soon-Shiong, 60, said he gained from Abraxane, the cancer treatment he developed and sold to Celgene Corp. in 2010 for $2.9 billion. The medicine wraps a chemotherapy used to kill tumors in a protein called human serum albumin that penetrates the walls of cancer cells. Celgene reported last week that the drug helped patients with advanced pancreatic cancer live a median 1.8 months longer than a standard treatment, a benefit for people battling one of the deadliest cancers. Soon-Shiong said he wants to extend that benefit by combining new diagnostic technologies and therapeutic strategies to improve care.] “It took 23 years from Abraxane being conceived to us showing now with conclusiveness that it works in pancreatic cancer,” Soon-Shiong said. “We cannot afford as a society to wait another 23 years to make sure that the patients get the right care, at the right time, at the right place.” Since selling his company, Abraxis BioScience, to Summit, N.J.-based Celgene in 2010, Soon-Shiong has branched into other endeavors, such as buying a 5 percent stake in the L.A. Lakers. Return to Medicine Soon-Shiong’s latest move returns him to his roots in medicine. NantOmics, funded primarily by Soon- Shiong’s California Capital Equity fund, seeks to develop medicines called kinase inhibitors that target multiple proteins to combat cancer...